Dajun Yang
31Patents
4h-index
45Co-inventors
63Inventor score
Filing activity: Aug 16, 1999 → Dec 18, 2020
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6703382B2 | Small molecule inhibitors targeted at Bcl-2 | Human Necessities | 66 | Expired |
| US7354928B2 | Small molecule inhibitors targeted at Bcl-2 | Human Necessities | 15 | Expired |
| US7432304B2 | Small molecule antagonists of Bcl-2 family proteins | Human Necessities | 7 | Expired |
| US8557812B2 | Small molecule inhibitors of anti-apoptotic BCL-2 family members and the uses thereof | Chemistry; Metallurgy | 5 | Active |
| US6143740A | Heregulin antagonists and methods for their use | Chemistry; Metallurgy | 4 | Expired |
| US7910621B2 | Small molecule antagonists of XIAP family proteins | Chemistry; Metallurgy | 2 | Active |
| US7226991B1 | Phenylalanine derivatives | Human Necessities | 2 | Expired |
| US11850239B2 | MDM2 inhibitor and a platinum compound for cancer treatment | Human Necessities | 1 | Active |
| US11478469B2 | Combination product of BCL-2 inhibitor and MDM2 inhibitor and use thereof in the prevention and/or treatment of diseases | Human Necessities | 1 | Active |
| US9783539B2 | Indoloquinolone compounds as anaplastic lymphoma kinase (ALK) inhibitors | Human Necessities | 1 | Active |
| US8163805B2 | Small molecule antagonists of Bcl-2 family proteins | Human Necessities | 1 | Active |
| US11452716B2 | Pharmaceutical composition and use thereof | Human Necessities | 1 | Active |
| US11395815B2 | Compound for treating osteoarthritis | Chemistry; Metallurgy | 0 | Active |
| US12083136B2 | Combination of BCL-2/BCL-XL inhibitors and chemotherapeutic agent and use thereof | Human Necessities | 0 | Active |
| US12194024B2 | Pharmaceutical composition of MDM2 inhibitor and use thereof for preventing and/or treating disease | Chemistry; Metallurgy | 0 | Active |
| US11298339B2 | Bisdiazabicyclo compound for treatment and/or prevention of hepatitis virus-related diseases or disorders | Emerging Cross-Sectional Technologies | 0 | Active |
| US11478470B2 | Combination product of Bcl-2 inhibitor or Bcl-2/Bcl-xL dual inhibitor and BTK inhibitor and use thereof in the prevention and/or treatment of diseases | Human Necessities | 0 | Active |
| US11491167B2 | Combination product of Bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases | Human Necessities | 0 | Active |
| US6951915B2 | Redox-stable, non-phosphorylated cyclic peptide inhibitors of SH2 domain binding to target protein, conjugates thereof, compositions and methods of synthesis and use | Human Necessities | 0 | Expired |
| US12186304B2 | Method for treating cancer by combination of IAP inhibitor and modulator of immune checkpoint molecule | Chemistry; Metallurgy | 0 | Active |
| US12268665B2 | Combination of immunotherapies with MDM2 inhibitors | Human Necessities | 0 | Active |
| US12287338B2 | Method and compositions for predicting anti-cancer efficacy of compounds targeting apoptosis pathway | Physics | 0 | Active |
| US12343352B2 | N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitors | Chemistry; Metallurgy | 0 | Active |
| US12370197B2 | Combination product of a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases | Human Necessities | 0 | Active |
| US12233047B2 | Pharmaceutical combination and use thereof | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.